Philip Morris International shares rose 6.3% after the U.S. FDA authorized its ZYN nicotine pouches as modified risk tobacco products, making ZYN the first and only nicotine pouch brand with that status in the U.S. The FDA recognized that switching completely from cigarettes to ZYN reduces exposure to harmful chemicals linked to major smoking-related diseases. This decision gives Philip Morris a distinct regulatory and scientific edge in the fast-growing smoke-free segment. The authorization, alongside the April 2026 renewal of modified risk status for IQOS and HEETS, further validates the company's reduced-exposure platform in the U.S. market.
Philip Morris International IncFDA granted ZYN modified risk status, giving Philip Morris a regulatory edge in the smoke-free segment.